rker development and precision medicine strategies for early stage clinical programs. Dr. Power led major external partnerships at Pfizer including Yale/Pfizer Bioimaging Alliance and Pfizer/NIH/NCATS’ New Therapeutic Uses Initiative, and his group developed and delivered successful collaborations with major academic institutions including University of Cambridge, Karolinska Institutet, University College London, and Washington University in St. Louis. During more than twenty years at Pfizer in both the UK and US, Dr. Power dev
rker development and precision medicine strategies for early stage clinical programs. Dr. Power led major external partnerships at Pfizer including Yale/Pfizer Bioimaging Alliance and Pfizer/NIH/NCATS’ New Therapeutic Uses Initiative, and his group developed and delivered successful collaborations with major academic institutions including University of Cambridge, Karolinska Institutet, University College London, and Washington University in St. Louis. During more than twenty years at Pfizer in both the UK and US, Dr. Power dev